CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 14, 2006--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced that it has expanded its multinational clinical trial of depsipeptide (FK228) for the treatment of cutaneous T-cell lymphoma (CTCL) to include clinical sites in the United States in addition to the active clinical sites in the United Kingdom, Poland, and Germany.
